

entered, considered and made of record. Applicants respectfully request reconsideration and allowance of the pending claims in light of the amendments and remarks presented herein.

AMENDMENTS

In the claims

Please cancel claims 73, 74, 78-80, 84-87 and 89-91, without prejudice or disclaimer.

Please amend claims 75, 81, 88, 92, and 109 as follows.

Sub 1
75. (Amended) [The primer of claim 73] An oligonucleotide primer tagged with a chromophore or fluorophore, said chromophore or fluorophore attached so as to allow chain extension by a polymerase, wherein the tagged primer has been base-paired to a template.

Sub 2
81. (Amended) [The set of primers of claim 78] A set of oligonucleotide primers comprising one or more oligonucleotide primers tagged with a chromophore or fluorophore, said chromophore or fluorophore attached so as to allow chain extension by a polymerase, wherein each tagged primer has been base-paired to a template.

Sub 3
88. (Amended) [The set of reagents of claim 84.] A set of reagents comprising oligonucleotide primers tagged with one or more chromophores or fluorophores, said chromophores or fluorophores attached so as to allow chain extension by a polymerase, and said set of reagents further comprising a polymerase.

Sub 4
92. (Amended) [The oligonucleotide of claim 89] An extended oligonucleotide comprising an oligonucleotide primer tagged with a chromophore or fluorophore, said

E4
cont.
chromophore or fluorophore attached so as to allow chain extension by a polymerase, wherein
the tagged primer has been hybridized to a template and extended in length.

E5 Sub E
109. (Thrice amended) A chain termination [DNA sequencing reaction] method
comprising use of the oligonucleotide of claim 105.

REMARKS

Claims 73-107, 109-111, and 118-132 were previously pending in this application.

Claims 112-117 have been withdrawn from consideration as a result of a restriction requirement.

By virtue of this amendment, claims 73, 74, 78-80, 84-87 and 89-91 are cancelled and claims 75, 81, 88, 92, and 109 are amended. The amendments to claims 75, 81, 88, 92, and 109 may be properly entered, as a result of the concurrent filing of a Request for Removal of Finality pursuant to 37 C.F.R. § 1.129(a). Accordingly, claims 75-77, 81-83, 88, 92-107, 109-111, and 118-132 are currently pending.

The cancellation of claims 73, 74, 78-80, 84-87 and 89-91 and the amendment of claims 75, 81, 88, 92, and 109 are not to be construed as a dedication to the public of the subject matter of those claims as previously presented. Applicants expressly reserve their right to file one or more continuing applications under 35 U.S.C. § 120 with claims directed to this subject matter.

Applicants acknowledge withdrawal of the rejection of claims 76, 77, 82, 83, 105-107 and 109-111 under 35 U.S.C. § 112, second paragraph; withdrawal of the rejection of claims 73-75, 84-86, 89, 90, 101, 102 and 104 under 35 U.S.C. § 102(b); and withdrawal of the rejection of claims 76-83, 87, 88, 91-100, 105-107 and 109-111 under 35 U.S.C. § 103(a) as set forth on pages 2 and 3 of the previous Office Action.